Welcome to our dedicated page for Vincerx Pharma news (Ticker: VINC), a resource for investors and traders seeking the latest updates and insights on Vincerx Pharma stock.
Vincerx Pharma Inc (VINC) delivers innovative oncology therapies through clinical-stage ADC and SMDC development. This page provides investors and researchers with verified updates on the company's scientific progress and corporate milestones.
Access real-time announcements including clinical trial results, regulatory developments, and strategic partnerships. Our curated news collection ensures efficient tracking of pipeline advancements for candidates like VIP236 (SMDC) and VIP943 (ADC), alongside updates on the VersAptx bioconjugation platform.
Key categories include treatment innovations, research collaborations, and financial disclosures. All content is sourced from official releases to maintain accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Vincerx Pharma's latest developments in targeted cancer therapies. Check regularly for updates on novel approaches to hematologic malignancies and solid tumor treatments.
Vincerx Pharma (VINC) has announced its intention to delist from Nasdaq and deregister with the SEC. The company received notice from Nasdaq on April 14, 2025, citing non-compliance with the minimum bid price requirement of $1.00 per share over 30 consecutive business days.
Trading of Vincerx's common stock was inadvertently suspended on April 16, 2025, but will resume on April 21, 2025, before being permanently suspended on April 23, 2025. The company plans to file a Form 25 for delisting around April 28, 2025.
Notably, Vincerx's board of directors has determined that dissolving, liquidating, and winding up the company's operations is in the best interest of stockholders. The company will not appeal Nasdaq's determination or seek listing on another exchange. Following the Form 25 effectiveness, Vincerx will file a Form 15 to deregister with the SEC.
Vincerx Pharma (Nasdaq: VINC) has announced the termination of its non-binding Letter of Intent (LOI) with Global Digital Holdings Inc. (QumulusAI) regarding a potential merger. Following this development, the company's board has authorized management to begin wind-down activities and explore asset monetization and out-licensing opportunities.
Acting CEO Raquel Izumi, Ph.D., acknowledged the support of investigators, patients, employees, and partners, noting that while adverse market conditions prevented further program development, their Phase 1 trials benefited cancer patients with therapeutic options.
Vincerx Pharma (VINC) has entered into a non-binding letter of intent for a business combination with QumulusAI, a private high-performance computing infrastructure company. The proposed reverse triangular merger would result in QumulusAI becoming publicly traded, with QumulusAI stockholders owning 95% and Vincerx shareholders retaining 5% of the combined company.
The deal values QumulusAI at approximately $285 million and Vincerx at $15 million. As part of the agreement, QumulusAI may invest up to $1.5 million in Vincerx equity before closing. The combined company's board will consist of seven QumulusAI-designated members, who will also determine senior management composition.
The parties have agreed to a 30-day exclusivity period for negotiations, subject to due diligence, board approvals, and other customary closing conditions including Nasdaq listing requirements.
Vincerx Pharma (NASDAQ: VINC) announced the termination of a previously signed binding Term Sheet for a reverse merger transaction with Oqory and Vivasor. In response, the board of directors will evaluate strategic alternatives, including:
- Out-licensing opportunities
- Merger and acquisition possibilities
- Sale of assets and technologies
- Potential winding down of operations
The company reported approximately $3.9 million in cash as of February 26, 2025, with an expected cash runway through late Q2 2025.
Vincerx Pharma (VINC) and Oqory announced promising Phase 1a/1b data for OQY-3258, an anti-TROP2 antibody drug conjugate (ADC), and provided insights into their proposed strategic merger. The drug is currently being evaluated in three clinical trials, including two Phase 3 studies.
Key clinical results from the Phase 1a/1b study of approximately 150 patients showed: 80% confirmed overall response rate in previously untreated TNBC patients (n=35); 27% confirmed ORR in late-stage TNBC patients (n=37); and 39% confirmed ORR in HR+/HER2- breast cancer patients (n=58). Notably, the drug demonstrated a 41% intracranial ORR in patients with brain metastases.
OQY-3258 showed a favorable safety profile with manageable hematologic toxicities and no Grade ≥3 rash or interstitial lung disease/pneumonitis. The merger aims to advance OQY-3258 into global Phase 3 trials and develop next-generation ADCs.
Vincerx Pharma (VINC) has announced a 1-for-20 reverse stock split of its common stock, effective January 27, 2025, at 4:01 p.m. ET. The split was approved by stockholders on January 16, 2025. Trading on the split-adjusted basis will begin on January 28, 2025, under the same symbol but with a new CUSIP number.
The reverse split will reduce outstanding shares from approximately 44.8 million to 2.2 million. No fractional shares will be issued; instead, affected stockholders will receive cash payments. Proportionate adjustments will be made to equity awards, warrants, and shares under equity incentive plans. Continental Stock Transfer & Trust Company will serve as the exchange agent.
Vincerx Pharma (VINC) has entered into a binding term sheet to merge with Oqory, a private clinical-stage company developing Antibody-drug Conjugates (ADCs) for oncology treatments. Post-merger, Oqory shareholders will own 95% of the combined entity, while Vincerx holders will retain 5%. The deal values Vincerx at $13.66 million and requires a minimum $20 million equity offering.
Oqory will provide $1.5 million interim financing in two tranches: $1 million funded through common stock and warrants, and $500,000 by January 31, 2025. Oqory's anti-TROP2 ADC has shown promising clinical results, including 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer patients, with favorable safety profiles.
Vincerx Pharma (VINC) announced cost-control measures and strategic alternatives exploration to support its Phase 1 study of VIP943, a CD123-targeted antibody-drug conjugate. The clinical trial has shown promising results, with one acute myeloid leukemia patient achieving CRi and one high-risk myelodysplastic syndrome patient achieving CRL out of nine evaluable patients. The company will implement a 55% workforce reduction to focus resources on VIP943's advancement.
Strategic options under consideration include out-licensing, mergers and acquisitions, reverse mergers, and asset sales. The company reported approximately $8.4 million in cash, cash equivalents, and marketable securities as of October 31, 2024. Additional cohort results are expected by early Q1 2025.
Vincerx Pharma reported Q3 2024 financial results and clinical program updates. The company continues enrollment in Phase 1 study of VIP943, showing promising results with two complete responses in AML and MDS patients. Cash position stands at $10.1M as of September 30, 2024, expected to last into early 2025. Q3 net loss was $7.8M ($0.17 per share), compared to $9.0M ($0.42 per share) in Q3 2023. R&D expenses decreased to $3.9M from $6.1M year-over-year, while G&A expenses increased slightly to $3.9M from $3.5M.
Vincerx Pharma (Nasdaq: VINC) reported positive initial clinical data from its ongoing VIP943 Phase 1 dose-escalation study in relapsed/refractory acute myeloid leukemia (AML), higher-risk myelodysplastic syndrome (HR-MDS), and B-cell acute lymphoblastic leukemia (B-ALL). The study has enrolled 22 patients to date, with two complete responses observed so far. VIP943 has shown favorable safety and tolerability, with no dose-limiting toxicities reported.
The company also provided updates on its VIP236 and enitociclib programs. VIP236 showed promising monotherapy duration of response in advanced cancer patients, while enitociclib demonstrated a 57% overall response rate in a Phase 1 study for relapsed/refractory lymphoma. Vincerx is focusing its resources on the continued development of VIP943 and expects its cash runway to extend into early 2025.
